Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VSEE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Related Party Transaction (new) — The company sold its wholly-owned subsidiary to its own co-CEO and chairman in a related party transaction with unclear economic valuation.
- Departure of CEO (new) — Co-CEO Milton Chen resigned effective May 31, 2026, concurrent with acquiring subsidiary VSee Lab, though the company states the departure was amicable.
VSee Health sells subsidiary to departing co-CEO Chen for 2.87M shares
Filed June 5, 2026 · Period ending May 31, 2026 · ~1 min read
Key Changes
-
high
Company sold wholly-owned subsidiary VSee Lab to co-CEO Milton Chen on May 31, 2026, in exchange for 2.87 million shares of common stock he owned, effectively executing a stock buyback tied to a divestiture.
Item 1.01 verify on EDGAR → -
high
Milton Chen resigned as co-CEO and board chairman effective May 31, 2026, concurrent with the VSee Lab acquisition. Dr. Imoigele Aisiku, the other co-CEO, was appointed sole CEO and chairman.
Item 5.02 verify on EDGAR → -
medium
Chen assumed responsibility for VSee Lab's unpaid debts and liabilities post-closing, while the company retains liability for pre-closing taxes and obligations.
Item 1.01 verify on EDGAR → -
high
Pro forma financials filed showing the transaction's impact on Q1 2026 and full-year 2025 results, indicating material effect on company's financial position.
Item 2.01 verify on EDGAR → -
low
The stock transaction qualified as a private placement under Section 4(a)(2) and Regulation D, exempt from SEC registration requirements.
Item 3.02 verify on EDGAR →
Summary
VSee Health executed an unusual transaction on May 31, 2026: selling its wholly-owned subsidiary VSee Lab to co-CEO Milton Chen in exchange for 2.87 million shares of company stock he owned. Chen simultaneously resigned as co-CEO and board chairman, with Dr. Imoigele Aisiku elevated from co-CEO to sole CEO and chairman.
The deal effectively functions as both a divestiture and a stock buyback, reducing shares outstanding while spinning off a business unit. Retail investors should note two concerns. First, the filing provides no financial details about VSee Lab's revenue, profitability, or strategic importance, making it impossible to assess whether shareholders received fair value.
Second, the related-party nature of the transaction—selling to an insider who then departs—raises questions about conflicts of interest and whether independent directors adequately protected shareholder interests. Chen assumed VSee Lab's future liabilities, but the company retains pre-closing obligations. Watch for the next 10-Q filing, which should reveal VSee Lab's historical financial contribution and explain how the divestiture affects ongoing operations. Investors should also monitor whether the leadership consolidation under Dr. Aisiku leads to strategic changes or operational improvements.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Pursuant to the Purchase Agreement, Mr. Chen agreed to purchase, and the Company agreed to sell to Mr. Chen, on the May 31, 2026 (the “Closing Date”), all of the equity securities of VSee Lab (the “VSee Lab Stock”), free and clear of all liens and encumbrances.
The company sold its wholly-owned subsidiary VSee Lab to co-CEO Milton Chen on May 31, 2026.
Added in current filing · verify on EDGAR →
In connection with the execution of the Purchase Agreement, Mr. Chen resigned as co-Chief Executive Officer and chairman of the board of directors of the Company, effective as of the Closing Date.
Milton Chen resigned as co-CEO and board chairman effective May 31, 2026, concurrent with acquiring VSee Lab. This represents significant leadership change, leaving the company without its chairman and one of two co-CEOs. The filing does not identify a successor or interim leadership.
Event · Item 2.01 — Completion of Acquisition or Disposition of Assets
Item 2.01 — Completion of Acquisition or Disposition of Assets filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 2.01.
The company completed an acquisition or disposition of assets as of May 31, 2026. The specific details of the transaction are referenced in Item 1.01 of this same 8-K filing, which is not included in the provided text. This represents a material corporate event that changed the company's asset base or business structure.
Added in current filing · verify on EDGAR →
Filed as Exhibit 99.1 to this Current Report on Form 8-K is the unaudited pro forma condensed consolidated balance sheet of the Company as of March 31, 2026 and the unaudited pro forma condensed consolidated statements of operations of the Company for the three months ended March 31, 2026, and the year ended December 31, 2025, in each case giving effect to the transaction described under Item 1.01 of this Current Report on Form 8-K.
The company filed pro forma financial statements showing what its balance sheet as of March 31, 2026 and its income statements for Q1 2026 and full year 2025 would have looked like if the acquisition or disposition had occurred earlier. These pro forma statements help investors understand the financial impact of the transaction on the combined entity.
Event · Item 3.02 — Unregistered Sales of Equity Securities
VSEE HEALTH disclosed unregistered sales of common stock under a purchase agreement via private placement exemption.
Added in current filing · verify on EDGAR →
The Common Stock to be issued in the connection with the Purchase Agreement will be issued in transactions exempt from registration under Section 4(a) (2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a) (2) of the Securities Act, and other applicable requirements were met.
The company is issuing common stock under a purchase agreement without registering the shares with the SEC. The issuance qualifies for a private placement exemption under Section 4(a)(2) and Regulation D because it does not constitute a public offering. This is a common method for raising capital from accredited or institutional investors without the time and expense of a registered offering.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Mr. Chen’s resignation was not because of any disagreement between Mr. Chen and the Company on any matter relating to the Company’s operations, policies or practices.
Mr. Chen resigned as CEO. The company explicitly states his departure was not due to any disagreement with the company regarding operations, policies, or practices, suggesting an amicable separation.
Added in current filing · verify on EDGAR →
Concurrently with Mr. Chen’s resignation, Dr. Imoigele Aisiku, the Company’s co-Chief Executive Officer, was appointed as the sole Chief Executive Officer and the chairman of the board of directors of the Company, effective immediately.
Dr. Imoigele Aisiku, previously co-CEO, has been promoted to sole CEO and also appointed chairman of the board. This consolidates leadership under a single executive who was already familiar with company operations.
Event · Item 9.01 — Financial Statements and Exhibits
VSee Health entered into a stock purchase agreement with Milton Chen on May 31, 2026, and filed pro forma financials.
Added in current filing · verify on EDGAR →
Stock Purchase Agreement, dated May 31, 2026, by and between VSee Health, Inc. and Milton Chen.
VSee Health disclosed a stock purchase agreement with Milton Chen dated May 31, 2026. The 8-K does not provide details about the transaction terms, purchase price, or number of shares involved. The filing includes pro forma financials suggesting this may be a material transaction requiring financial impact disclosure.
Added in current filing · verify on EDGAR →
Unaudited pro forma condensed consolidated balance sheet of VSee Health Inc. as of March 31, 2026, and the unaudited pro forma condensed consolidated statements of operations of VSee Health Inc. for the three months ended March 31, 2026, and the year ended December 31, 2025.
The company filed unaudited pro forma consolidated financials as of March 31, 2026, and for the three months ended March 31, 2026, and year ended December 31, 2025. Pro forma statements typically reflect the financial impact of a significant transaction as if it had occurred at an earlier date, suggesting the stock purchase agreement with Milton Chen is material enough to warrant adjusted financial presentation.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify